A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na ïve chronic hepatitis B in South Korea
Chronic hepatitis B (CHB) is the most common chronic viral infection worldwide, affecting approximately 350 million people.1 Because persistently high hepatitis B virus (HBV) replication is associated with an increased risk of compensated cirrhosis and hepatocellular carcinoma (HCC),2,3 replication-suppressing antiviral therapy is administered to patients with CHB to prevent liver-disease progression.4 As a matter of fact, oral antiviral agents, particularly entecavir (ETV), reduce the risk of long-term complications such as cirrhosis and HCC, ultimately improving survival compared to controls.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo Young Park Tags: Research Article Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Oral Cancer | South Korea Health | Study | Urology & Nephrology | Viread